CSIR technology platform for cancer precision medicine

Abstract

Dr. Deepak Balaji Thimiri Govindaraj has been selected for an e-Poster presentation at the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukaemia. The Conference is proposing a programme of leading-edge basic and clinical science where a panel of global experts in the field will provide numerous opportunities for formal and informal interactions to discuss the present and the future of CLL research. It is open to an international audience of biologists and clinicians, particularly welcoming those in-training. This translational research conference will explore the most recent advances in the understanding of the pathogenesis and clinical management of the disease. Open and spirited discussion on the most up-to-date information in the field is expected to understand how the many new biologic insights apply to the future of CLL. The main issue with current Ovarian Cancer (OvCa), Chronic lymphocytic leukemia (CLL) and Multiple Myeloma (MM) treatment is the eventual resistance to standard chemotherapy which ultimately leads to patient relapse. Overcoming platinum resistance is an unmet medical need in OvCa, CLL, MM patients which we plan to address with our technology pipeline. We propose a game changing, disruptive technology pipeline with which we will identify drugs and drug combinations for relapsed CLL, MM and OvCa patients who exhausted all other treatment options. Our technology pipeline includes strategies where we combine new microfluidic-based technology with our established high-throughput drug screening platform. Using our pipeline, we aim to identify drug combinations that can overcome platinum resistance and ultimately provide tailored-specific therapy options for CLL, MM and OvCa patients . Approach: The aim of the proposal is to establish robust drug screening platform which can identify drugs and drug combinations that are effective in precision medicine for individual CLL, MM and OvCa patients. We propose a strategy where we use combination of our newly established platform for drug screening with patient samples, flow cytometry-based signaling analysis, and microfluidics based single cell drug screening methodology towards precision medicine for ovarian cancer patients.